Skip to main content

Advertisement

SpringerLink
Log in

Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment

  • Commentary
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Given the prevalence of cardiovascular diseases (CVDs), as one of the most important non-communicable diseases (NCDs), the recognition of diagnostic biomarkers and potential treatment methods is very crucial. Today gut microbiota composition and its derived metabolites modification are known as one of the recent therapeutic strategies. Studies show that Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite that may be involved in the development of cardiovascular diseases, including ischemic disease and atherosclerosis, atrial fibrillation and arrhythmia, and heart failure. Due to existing some disagreements in this manner, future studies are needed to obtain a definitive sight of the association between this metabolite and CVDs. TMAO may be beneficial as a prognostic marker, which represents the degree of gut microbiota dysbiosis and subsequently CVD events and also different therapies methods based on TMAO and its metabolic pathways can be the target of clinical trial on cardiovascular disease and/or its prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7):e004947.

    Article  Google Scholar 

  2. Ejtahed HS, Angoorani P, Soroush AR, Hasani-Ranjbar S, Siadat SD, Larijani B. Gut microbiota-derived metabolites in obesity: a systematic review. Biosci Microbiota Food Health. 2020;39(3):65–76.

  3. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398.

    Article  Google Scholar 

  4. Zhang Y, Wang Y, Ke B, Du J. TMAO: how gut microbiota contributes to heart failure. Translational Research: The Journal of Laboratory and Clinical Medicine. 2021;228:109–25.

  5. Guasti L, Galliazzo S, Molaro M, Visconti E, Pennella B, Gaudio GV, et al. TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(1):201–7. 

  6. Qi J, You T, Li J, Pan T, Xiang L, Han Y, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med. 2018;22(1):185–94.

    Article  CAS  Google Scholar 

  7. Svingen GF, Zuo H, Ueland PM, Seifert R, Løland KH, Pedersen ER, et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. Int J Cardiol. 2018;267:100–6.

    Article  Google Scholar 

  8. Ufnal M, Zadlo A, Ostaszewski R. TMAO: A small molecule of great expectations. Nutrition. 2015;31(11–12):1317–23.

    Article  CAS  Google Scholar 

  9. Yang S, Li X, Yang F, Zhao R, Pan X, Liang J, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. 2019;10:1360.

    Article  CAS  Google Scholar 

  10. Meyer KA, Benton TZ, Bennett BJ, Jacobs DR Jr, Lloyd-Jones DM, Gross MD, et al. Microbiota-dependent metabolite trimethylamine N-oxide and coronary artery calcium in the coronary artery risk development in young adults study (CARDIA). J Am Heart Assoc. 2016;5(10):e003970.

    Article  Google Scholar 

  11. Skagen K, Trøseid M, Ueland T, Holm S, Abbas A, Gregersen I, et al. The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis. Atherosclerosis. 2016;247:64–9.

    Article  CAS  Google Scholar 

  12. Askarpour M, Hadi A, Bozorg ADK, Sadeghi O, Sheikhi A, Kazemi M, et al. Effects of L-carnitine supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Hum Hypertens. 2019;33(10):725–34.

    Article  CAS  Google Scholar 

  13. Wang Z-Y, Liu Y-Y, Liu G-H, Lu H-B, Mao C-Y. l-Carnitine and heart disease. Life Sci. 2018;194:88–97.

    Article  CAS  Google Scholar 

  14. Brown JM, Hazen SL. Meta-organismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol. 2014;25(1):48.

    Article  CAS  Google Scholar 

  15. Hasani-Ranjbar S, Larijani B. Human microbiome as an approach to personalized medicine. Altern Ther Health Med. 2017;23(6):8–9.

    PubMed  Google Scholar 

  16. Leshem A, Horesh N, Elinav E. Fecal microbial transplantation and its potential application in cardiometabolic syndrome. Front Immunol. 2019;10:1341.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Zahra Hoseini-Tavassol & Shirin Hasani-Ranjbar

Authors
  1. Zahra Hoseini-Tavassol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shirin Hasani-Ranjbar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZHT drafted the manuscript. SHR designed the study and helped to draft the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Shirin Hasani-Ranjbar.

Ethics declarations

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Conflict of interests

The authors declare that they have no conflict interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoseini-Tavassol, Z., Hasani-Ranjbar, S. Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment. J Diabetes Metab Disord 20, 1095–1097 (2021). https://doi.org/10.1007/s40200-021-00819-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-021-00819-x

Keywords

Search

Navigation